|
Sign In to gain access to subscriptions and/or personal tools.
|
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials
R A Rudick
Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research (Area U10), The Cleveland Clinic Foundation, Cleveland, Ohio, USA, rudickr{at}ccf.org
G Cutter
Center for Research Methodology and Biometrics, AMC Cancer Research Center, 1600 Pierce St., Lakewood, Colorado 80214, USA
S Reingold
Research Programs Department, National Multiple Sclerosis Society, 733 Third Avenue, New York, New York 10017, USA
With the advent and widespread use of partially effective disease modifying drug therapies for multiple sclerosis (MS), future clinical trials will undoubtedly test experimental interventions against standard therapy, or will test combinations of drugs against standard therapy. In either case, incremental progress in slowing disability progression in future MS clinical trials will require much larger sample sizes, more sensitive outcome measures, or a combination of the two. Because improved clinical outcome methods would likely accelerate progress in MS therapeutics, the National Multiple Sclerosis Society (NMSS) convened an international task force in 1994 to recommend improved clinical outcome measures. As the result of a two-year process of discussion and data analysis, the task force recommended the Multiple Sclerosis Functional Composite (MSFC) as a new clinical outcome measure for future MS trials. MSFC consists of timed tests of walking, arm function, and cognitive function, expressed as a single score along a continuous scale. The task force recommended that MSFC be included in future MS trials, and recommended a series of validation studies. Subsequent studies have provided evidence that MSFC correlates moderately with Expanded Disability Status Scale (EDSS), and that correlation is driven by strong correlations with the ambulatory function component; arm function and cognitive function correlate at lower levels with EDSS. The MSFC correlates better than EDSS with magnetic resonance imaging (MRI) variables, including brain atrophy, and shows significant correlation with patient-reported disease-related quality of life (QOL). MSFC and short-term change in MSFC correlate with future clinical and MRI status, and the strength of the correlations compares favorably with well-known cardiovascular risk factors. The studies in aggregate indicate that MSFC and MSFC change are clinically meaningful, and that MSFC has substantial advantages over alternative clinical outcome measures for MS clinical trials.
Key Words: EDSS • clinical trials • multiple sclerosis • multiple sclerosis functional composite • outcome measures
Multiple Sclerosis, Vol. 8, No. 5,
359-365 (2002)
DOI: 10.1191/1352458502ms845oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A Niklas, H Sebraoui, E Hess, A Wagner, and F Then Bergh
Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency
Multiple Sclerosis,
January 1, 2009;
15(1):
68 - 74.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B Brochet, M. Deloire, M Bonnet, E Salort-Campana, J. Ouallet, K. Petry, and V Dousset
Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study
Multiple Sclerosis,
November 1, 2008;
14(9):
1242 - 1249.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.A. Marrie and M. Goldman
Validity of performance scales for disability assessment in multiple sclerosis
Multiple Sclerosis,
November 1, 2007;
13(9):
1176 - 1182.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Khan
Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
Neurology,
May 29, 2007;
68(22_suppl_3):
S64 - S71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Bobholz, S. M. Rao, L. Lobeck, C. Elsinger, A. Gleason, J. Kanz, S. Durgerian, and E. Maas
fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume.
Neurology,
November 14, 2006;
67(9):
1640 - 1645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M M Nieuwenhuis, H Van Tongeren, P S Sorensen, and M Ravnborg
The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis
Multiple Sclerosis,
August 1, 2006;
12(4):
495 - 500.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. P. Sanfilipo, R. H.B. Benedict, B. Weinstock-Guttman, and R. Bakshi
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis
Neurology,
March 14, 2006;
66(5):
685 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin
The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Multiple Sclerosis,
February 1, 2006;
12(1):
24 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis
Neurology,
December 14, 2004;
63(11_suppl_5):
S3 - S11.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L Nicholl, J Hobart, L Dunwoody, F Cramp, and A Lowe-Strong
Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?
Multiple Sclerosis,
August 1, 2004;
10(4):
447 - 450.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(1_suppl):
S46 - S55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis,
May 1, 2004;
10(3_suppl):
S46 - S55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. J Thompson
Developing clinical outcome measures in multiple sclerosis: an evolving process
Multiple Sclerosis,
October 1, 2002;
8(5):
357 - 358.
[PDF]
|
|
|
|
|
